Please Wait.....
Report
Global Cardiovascular Drugs Market Report and Forecast 2023-2031
Market Report I 2023-04-20 I 147 Pages I EMR Inc.
Global Cardiovascular Drugs Market Report and Forecast 2023-2031
Global Cardiovascular Drugs Market Outlook
The global cardiovascular drugs market size attained a value of USD 64.97 billion in 2022. The market is anticipated to grow at a CAGR of 2.66% during the forecast period of 2023-2031, driven by the rising prevalence of cardiovascular diseases across the globe. The global cardiovascular drugs market share is anticipated to achieve a value of USD 82.24 billion by 2031.
Key Trends in Global Cardiovascular Drugs Market
- Technological advancements in drug delivery systems: The development of innovative drug delivery systems, such as transdermal patches, inhalation devices, and injectable formulations, is expected to revolutionize the way cardiovascular drugs are administered. This will not only improve patient compliance but also enhance drug efficacy and reduce the risk of adverse events.
- Increasing use of combination therapies: Combination therapies, which involve the use of two or more drugs to treat cardiovascular diseases, are becoming increasingly popular. This is because they offer several advantages over monotherapy, such as improved efficacy, reduced risk of adverse events, and simplified treatment regimens.
- Rise in demand for personalized medicine: With the increasing availability of genetic testing and biomarker analysis, personalized medicine is becoming a key trend in the cardiovascular drugs market. By tailoring treatment to an individual's specific genetic and biomarker profile, healthcare providers can improve treatment outcomes and reduce the risk of adverse events.
- Emergence of gene therapy: Gene therapy, which involves the use of genetic material to treat or prevent diseases, is a rapidly evolving field. It has the potential to offer a cure for certain types of cardiovascular diseases and may become a key treatment option in the future.
- Growing focus on preventive care: With the increasing burden of cardiovascular diseases, there is a growing focus on preventive care. This includes lifestyle modifications such as exercise and healthy eating, as well as the use of drugs to reduce the risk of cardiovascular events in high-risk individuals.
Overall, these trends are expected to shape the cardiovascular drugs market from 2023 to 2031 and drive innovation in the development of new treatments and drug delivery systems.
Cardiovascular Drugs Market Segmentations
Market Breakup by Drug Class
- Antihypertensive Drugs
- Anticoagulants
- Antiplatelet Agents
- Antihyperlipidemic Drugs
- Antiarrhythmic Drugs
- Others
Market Breakup by Indications
- Hypertension
- Coronary artery disease
- Heart Failure
- Arrhythmias
- Dyslipidaemia
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Segmentation by Drug Type
- Branded
- Generics
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospitals Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Market Segmentation by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Cardiovascular Drugs Market Analysis
The market is expected to experience significant growth in North America and Europe due to the high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to a large population base, increasing disposable income, and a rise in awareness about cardiovascular diseases.
The market is expected to experience significant growth in North America and Europe due to the high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to a large population base, increasing disposable income, and a rise in awareness about cardiovascular diseases.
Cardiovascular diseases, which are the leading cause of death globally, have become a major public health issue. As a result, there has been a significant increase in the demand for cardiovascular drugs. In conclusion, the cardiovascular drugs market is expected to witness significant growth from 2023 to 2031 due to an increase in the prevalence of cardiovascular diseases and a growing demand for effective treatment options. The market is expected to be driven by factors such as technological advancements, the development of innovative drugs, and a rise in awareness about cardiovascular diseases.
Key Players in the Global Cardiovascular Drugs Market
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- F. Hoffmann-La Roche Ltd.
- Fresenius Kabi AG
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Zydus Group
- Pfizer Inc.
- Lupin
- GSK Plc
- Glenmark Pharmaceuticals Inc.
- Capricor Therapeutics
- Zensun
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cardiovascular Drugs Market Overview
3.1 Global Cardiovascular Drugs Market Historical Value (2016-2022)
3.2 Global Cardiovascular Drugs Market Forecast Value (2023-2031)
4 Global Cardiovascular Drugs Market Landscape
4.1 Global Cardiovascular Drugs Company Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cardiovascular Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End User
4.2.5 Analysis by Distribution Channel
5 Global Cardiovascular Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cardiovascular Drugs Market Segmentation
6.1 Global Cardiovascular Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Antihypertensive Drugs
6.1.3 Anticoagulants
6.1.4 Antiplatelet Agents
6.1.5 Antihyperlipidemic Drugs
6.1.6 Antiarrhythmic Drugs
6.1.7 Others
6.2 Global Cardiovascular Drugs Market by Indications
6.2.1 Market Overview
6.2.2 Hypertension
6.2.3 Coronary artery disease
6.2.4 Heart Failure
6.2.5 Arrhythmias
6.2.6 Dyslipidemia
6.2.7 Others
6.3 Global Cardiovascular Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Cardiovascular Drugs Market by Drug Type
6.4.1 Market Overview
6.4.2 Branded
6.4.3 Generics
6.5 Global Cardiovascular Drugs Market by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Homecare
6.5.4 Specialty Clinics
6.5.5 Others
6.6 Global Cardiovascular Drugs Market by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospitals Pharmacy
6.6.3 Online Pharmacy
6.6.4 Retail Pharmacy
6.6.5 Others
6.7 Global Cardiovascular Drugs Market by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Cardiovascular Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cardiovascular Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cardiovascular Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cardiovascular Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cardiovascular Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 F. Hoffmann-La Roche Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Fresenius Kabi AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bayer AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sun Pharmaceutical Industries Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Novartis AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mylan N.V.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Teva Pharmaceutical Industries Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Zydus Group
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Lupin
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 GSK Plc
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Glenmark Pharmaceuticals Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Capricor Therapeutics
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Zensun
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Cardiovascular Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security